Allos Therapeutics Files Shelf Registration Statement
23 Maio 2007 - 6:55PM
PR Newswire (US)
WESTMINSTER, Colo., May 23 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (NASDAQ:ALTH) announced today that it has filed
a universal shelf registration statement with the Securities and
Exchange Commission (SEC) that, if declared effective by the SEC,
will allow the Company to sell, from time to time, up to $150
million of its common stock, preferred stock, depository shares,
debt securities and/or warrants, either individually or in units,
in one or more offerings. As of the date of this release, the
Company has no specific plans to offer the securities covered by
the registration statement and the Company is not required to offer
the securities in the future pursuant to the registration
statement. The terms of any offering under the registration
statement will be established at the time of the offering. Proceeds
from the sale of any securities will be used for the purposes
described in a prospectus supplement filed at the time of an
offering. If and when the SEC declares this registration statement
effective, the Company intends to retire the unused portion of its
previous shelf registration statement that was declared effective
by the SEC in 2006. The Company expects to use the net proceeds
from any sale of securities under the registration statement to
fund the costs of its clinical and pre-clinical research and
development activities, both on-going and planned, to support the
potential commercialization of EFAPROXYN in the event the Company
obtains regulatory approval to market EFAPROXYN, the manufacture of
pre-clinical and clinical drug supply and for general corporate
purposes, including working capital. A shelf registration statement
relating to these securities was filed today with the SEC but has
not yet become effective. The securities offered by the Company
pursuant to the registration statement may not be sold, nor may
offers to buy the securities be accepted prior to the time the
registration statement becomes effective. This press release shall
not constitute an offer to sell or the solicitation of an offer to
buy, nor shall there be any sale of the securities in any
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such jurisdiction. About Allos Therapeutics,
Inc. Allos Therapeutics, Inc. (ALTH) is a biopharmaceutical company
focused on the development and commercialization of small molecule
therapeutics for the treatment of cancer. The Company has two
product candidates in late-stage clinical development: EFAPROXYN
(efaproxiral), a radiation sensitizer currently under evaluation in
a pivotal Phase 3 trial in women with brain metastases originating
from breast cancer, and PDX (pralatrexate), a novel antifolate
currently under evaluation in a pivotal Phase 2 trial in patients
with relapsed or refractory peripheral T-cell lymphoma. The Company
is also evaluating RH1, a targeted chemotherapeutic agent, in a
Phase 1 trial in patients with advanced solid tumors. For
additional information, please visit the Company's website at
http://www.allos.com/. Safe Harbor Statement This press release
contains forward-looking statements that are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. You can identify forward-looking statements by
terminology such as "may," "will," "should," "expects," "intends,"
"plans," "anticipates," "believes," "estimates," "predicts,"
"projects," "potential," "continue," and other similar terminology
or the negative of these terms, but their absence does not mean
that a particular statement is not forward-looking. Such
forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties that may cause actual
results to differ materially from those anticipated by the
forward-looking statements. These risks and uncertainties include,
among others, those described in the "Risk Factors" section of the
Company's Annual Report on Form 10-K for the year ended December
31, 2006 and in the Company's other periodic reports and filings
with the Securities and Exchange Commission. The Company cautions
investors not to place undue reliance on the forward-looking
statements contained in this press release. All forward-looking
statements are based on information currently available to the
Company on the date hereof, and the Company undertakes no
obligation to revise or update these forward-looking statements to
reflect events or circumstances after the date of this
presentation, except as required by law. DATASOURCE: Allos
Therapeutics, Inc. CONTACT: Derek Cole, Vice President, Investor
Relations, +1-720-540-5367, , or Jennifer Neiman, Senior Manager,
Corporate Communications, +1-720-540-5227, , both of Allos
Therapeutics, Inc. Web site: http://www.allos.com/
Copyright
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024